Viatris Inc. (VTRS) Return on Equity (ROE): -2.02%
Is Viatris Inc.’s return on equity (ROE) high or low?
Viatris Inc.'s return on equity (ROE) of -2.02% is 54% above its 5-year average of -4.38%, around the middle of its 5-year range (-23.89%–9.86%).
As of Sunday, June 21, 2026. 85.20% above its 12-month average of -13.64%.
VTRS Return on Equity (ROE) Chart
VTRS Average Return on Equity (ROE) Chart
VTRS Current vs Average Return on Equity (ROE) Chart
VTRS Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-2.02%
RETURN ON EQUITY (ROE) AVG TTM
-13.64%
RETURN ON EQUITY (ROE) AVG 3Y
-4.29%
RETURN ON EQUITY (ROE) AVG 5Y
-4.38%
RETURN ON EQUITY (ROE) AVG 10Y
-1.37%
RETURN ON EQUITY (ROE) AVG 15Y
7.52%
RETURN ON EQUITY (ROE) AVG 20Y
5.93%
CURRENT VS TTM AVG
+85.20%
CURRENT VS 3Y AVG
+52.91%
CURRENT VS 5Y AVG
+53.86%
CURRENT VS 10Y AVG
-47.66%
CURRENT VS 15Y AVG
-126.87%
CURRENT VS 20Y AVG
-134.08%
VTRS Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $17.90B | -2.02% | -13.64% | -4.29% | -4.38% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 6.01% | 6.40% | 5.73% | 4.16% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Incyte Corporation (INCY)vs › | $19.62B | 25.79% | 12.92% | 11.29% | 9.83% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 10.79% | 9.71% | 9.35% | 12.84% |
| DaVita Inc. (DVA)vs › | $13.34B | -114.70% | 329.18% | 200.63% | 164.66% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 76.95% | 73.63% | 65.34% | 49.74% |
| Solventum Corporation (SOLV)vs › | $13.06B | 28.82% | 23.51% | 17.50% | 13.68% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 10.36% | 10.54% | 10.84% | 19.93% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 21.82% | 18.68% | 17.25% | 16.03% |
Return Analysis
ROE
-2.0%
ROA
-0.8%
Viatris Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Viatris Inc. (VTRS)?
- The return on equity (ROE) for VTRS stock is -2.02%.
- Is Viatris Inc.'s return on equity (ROE) high or low?
- Viatris Inc.'s return on equity (ROE) of -2.02% is 54% above its 5-year average of -4.38%, around the middle of its 5-year range (-23.89%–9.86%).
- What is the TTM average return on equity (ROE) for Viatris Inc. (VTRS)?
- The TTM average return on equity (ROE) for VTRS stock is -13.64%.
- What is the 3Y average return on equity (ROE) for Viatris Inc. (VTRS)?
- The 3Y average return on equity (ROE) for VTRS stock is -4.29%.
- What is the 5Y average return on equity (ROE) for Viatris Inc. (VTRS)?
- The 5Y average return on equity (ROE) for VTRS stock is -4.38%.
- What is the 10Y average return on equity (ROE) for Viatris Inc. (VTRS)?
- The 10Y average return on equity (ROE) for VTRS stock is -1.37%.
- What is the 15Y average return on equity (ROE) for Viatris Inc. (VTRS)?
- The 15Y average return on equity (ROE) for VTRS stock is 7.52%.
- What is the 20Y average return on equity (ROE) for Viatris Inc. (VTRS)?
- The 20Y average return on equity (ROE) for VTRS stock is 5.93%.
Viatris Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -23.89% |
| 2024-12-31 | -3.40% |
| 2023-12-31 | 0.27% |
| 2022-12-31 | 9.86% |
| 2021-12-31 | -6.19% |
| 2020-12-31 | -2.92% |
| 2019-12-31 | 0.14% |
| 2018-12-30 | 2.90% |
| 2017-12-30 | 5.23% |
| 2016-12-30 | 4.32% |
| 2015-12-30 | 8.68% |
| 2014-12-30 | 28.55% |
| 2013-12-30 | 21.20% |
| 2012-12-31 | 19.18% |
| 2011-12-31 | 15.37% |
| 2010-12-31 | 9.58% |
| 2009-12-31 | 7.43% |
| 2008-12-31 | -7.11% |
| 2007-12-31 | -44.58% |
| 2006-03-31 | 23.43% |
| 2005-03-31 | 11.03% |
| 2004-03-31 | 20.16% |
Related Metrics
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith